Search: onr:"swepub:oai:DiVA.org:uu-372445" > SCOT :
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06891naa a2200733 4500 | |
001 | oai:DiVA.org:uu-372445 | |
003 | SwePub | |
008 | 190107s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3724452 URI |
024 | 7 | a https://doi.org/10.1038/s41416-018-0319-z2 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Robles-Zurita, Joseu Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland4 aut |
245 | 1 0 | a SCOT :b a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer |
264 | c 2018-11-13 | |
264 | 1 | b Springer Science and Business Media LLC,c 2018 |
338 | a print2 rdacarrier | |
520 | a BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer.METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken.RESULTS: The 3M arm is less costly (-4881; pound 95% CI: -6269; pound -3492) pound and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3M had lower QALYs than 6M (not statistically significant).CONCLUSIONS: Overall, 3M dominates 6M with no significant detrimental impact on QALYs. The results provide the economic case that a 3M treatment strategy should be considered a new standard of care. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Boyd, Kathleen A.u Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Briggs, Andrew H.u Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Iveson, Timothyu Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England4 aut |
700 | 1 | a Kerr, Rachel S.u Univ Oxford, Dept Oncol, Oxford, England4 aut |
700 | 1 | a Saunders, Mark P.u Christie Hosp, Manchester, Lancs, England4 aut |
700 | 1 | a Cassidy, Jimu Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Hollander, Niels Henriku Zealand Univ Hosp, Dept Oncol & Palliat Care, Radmandsengen 5, DK-4700 Naestved, Denmark4 aut |
700 | 1 | a Tabernero, Josepu Univ Autonoma Barcelona, CIBERONC, Vall dHebron Univ Hosp, Barcelona, Spain;Univ Autonoma Barcelona, CIBERONC, Inst Oncol VHIO, Barcelona, Spain4 aut |
700 | 1 | a Segelov, Evau Australasian Gastrointestinal Trials Grp AGITG, Melbourne, Vic, Australia;Monash Univ, Melbourne, Vic, Australia;Monash Hlth, Melbourne, Vic, Australia4 aut |
700 | 1 | a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim |
700 | 1 | a Harkin, Andreau Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Allan, Karenu Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a McQueen, Johnu Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Pearson, Sarahu Univ Oxford, OCTO, Dept Oncol, Oxford, England4 aut |
700 | 1 | a Waterston, Ashitau Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Medley, Louiseu Royal United Hosp, Bath, Avon, England4 aut |
700 | 1 | a Wilson, Charlesu Addenbrookes Hosp, Cambridge, England4 aut |
700 | 1 | a Ellis, Richardu Royal Cornwall Hosp NHS Trust, Truro, Cornwall, England4 aut |
700 | 1 | a Essapen, Sharadahu Royal Surrey Cty Hosp NHS Fdn Trust, St Lukes Canc Ctr, Guildford, Surrey, England4 aut |
700 | 1 | a Dhadda, Amandeep S.u Castle Hill Hosp, Kingston Upon Hull, N Humberside, England4 aut |
700 | 1 | a Hughes, Robu Mt Vernon Canc Ctr, Northwood, Middx, England4 aut |
700 | 1 | a Falk, Stephenu Bristol Canc Inst, Bristol, Avon, England4 aut |
700 | 1 | a Raouf, Sherifu Barking Havering & Redbridge Univ Hosp NHS Trust, Barking, England4 aut |
700 | 1 | a Rees, Charlotteu Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England4 aut |
700 | 1 | a Olesen, Rene K.u Zealand Univ Hosp, Dept Oncol & Palliat Care, Radmandsengen 5, DK-4700 Naestved, Denmark4 aut |
700 | 1 | a Propper, Davidu Queen Mary Univ London, Barts Canc Inst, London, England4 aut |
700 | 1 | a Bridgewater, Johnu UCL, London, England4 aut |
700 | 1 | a Azzabi, Ashrafu Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England4 aut |
700 | 1 | a Farrugia, Davidu Cheltenham Gen Hosp, Gloucestershire Oncol Ctr, Cheltenham, Glos, England4 aut |
700 | 1 | a Webb, Andrewu Brighton & Sussex Univ Hosp Trust, Brighton, E Sussex, England4 aut |
700 | 1 | a Cunningham, Davidu Royal Marsden, London, England4 aut |
700 | 1 | a Hickish, Tamasu Bournemouth Univ, Poole Hosp, Bournemouth, Dorset, England4 aut |
700 | 1 | a Weaver, Andrewu Oxford Univ Hosp Fdn Trust, Churchill Hosp, Oxford, England4 aut |
700 | 1 | a Gollins, Simonu North Wales Canc Treatment Ctr, Rhyl, Wales4 aut |
700 | 1 | a Wasan, Harpreet S.u Imperial Coll London, Hammersmith Hosp, London, England4 aut |
700 | 1 | a Paul, Jamesu Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut |
710 | 2 | a Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotlandb Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England4 org |
773 | 0 | t British Journal of Cancerd : Springer Science and Business Media LLCg 119:11, s. 1332-1338q 119:11<1332-1338x 0007-0920x 1532-1827 |
856 | 4 | u https://www.nature.com/articles/s41416-018-0319-z.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-372445 |
856 | 4 8 | u https://doi.org/10.1038/s41416-018-0319-z |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.